Tag: patient

EURUSD Weekly Summary (May 29)

Filed in Gold, Gold Bullion prices, silver by on May 28, 2010 0 Comments
EURUSD Weekly Summary (May 29)

EURUSD Weekly Summary Overall, the EURUSD was able to maintain its bearish outlook this week. Opened at 1.2546 on Monday, price closed lower at 1.2270 on Friday in a volatile and difficult market, especially for intra-day trading activity. On daily chart below we can see that price still move below the major trendline support, keep the bearish scenario testing 1.2000 key support area intact. However we have a strong support area around 1.2140/50 region where price bounced significantly higher after failed to move below that area in the last two weeks. Technically we need a clear break below that area to confirm the bearish continuation scenario towards 1.2000 area. On the upside, resistance is seen around 1.2470 followed by 1.2671 region. I think the situation lately shows that we need our patient and discipline more than any technical or fundamental factors. A difficult situation but give us a precious experience. Have a great weekend and see you guys next week.

Continue Reading »

Bailout Euphoria Is Evaporating

Filed in Gold, Gold Prices by on May 11, 2010 0 Comments
Bailout Euphoria Is Evaporating

Chief markets economist Kevin Gaynor  of RBS says the E.U.’s strategy  is “Bailouts rather than integration”. It is not solving the problem, E.U.  are just throwing money at it. Marek Belke, the E.U.  head at the IMF, compare the rescue package to a dose of morphine with the purpose to stabilize the patient. The real

Continue Reading »

Delcath Systems Surges on Phase III Clinical Data

Filed in Gold Market by on April 21, 2010 0 Comments

Delcath Systems (NASDAQ: DCTH ) surged 30% in after-hours trading Wednesday. The company announced positive clinical data for their proprietary liver cancer treatment system, called the Delcath Percutaneous Hepatic Perfusion (PHP) System. Delcath’s PHP system works by first isolating the patient’s liver from the rest of the circulatory system. This is accomplished using catheters and balloons, which are inserted via small incisions in the patient’s neck and legs. Highly-concentrated doses of chemotherapy drugs are then delivered directly to the diseased organ. After treatment, the blood is filtered and cleansed of potentially toxic drugs and returned to circulation. The system — which is unique as far as I know — allows doctors to target the liver with 10x higher doses of chemotherapy than are normally feasible. Since the drugs are targeted directly at the tumors, then filtered out of the bloodstream after treatment, DCTH thinks they can significantly increase dosage without increasing toxicity. It could prove to be an important life-extending development for patients who currently have few treatment options. The trial data announced this afternoon comes from Delcath’s phase III clinical trial, which enrolled patients who have melanoma that has spread to the liver. Patients who received treatment from the Delcath system had more than a 50% reduction in a primary study goal, “time to tumor reduction or death”. The results exceeded primary endpoint expectations and were statistically significant. In FDA-speak, that’s a good news for patients and investors. Here’s an excerpt from the company’s press release : Delcath Systems, Inc. (NASDAQ: DCTH), a development stage, oncology-focused, specialty pharmaceutical and medical device company, announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study’s primary endpoint of extended hepatic progression-free survival (hPFS) in patients with melanoma metastases to the liver based on an independently corroborated intent-to-treat analysis. Comparing treatment with the Delcath PHP System with melphalan to Best Alternative Care (BAC), based on independent core lab review of patient scans, the statistical analysis revealed that the PHP patients had a statistically significant longer median hPFS of 214 days compared to 70 days in the BAC arm. Reuters reports that the market for Delcath’s system to treat melanoma which has spread to the liver could be $745 million in the U.S. alone. Delcath is also proceeding with phase II clinical trials on primary liver cancers at the National Cancer Institute. The company’s current market cap was around $395m as of closing today (but it closed up 30% in after-hours trading). Full Trial Data To Be Announced June 5th While I’m bullish on Delcath (disclosure: I own the stock), it’s important to note that the full details of this trial won’t be available until June 5th, when the lead researcher presents at the American Society of Clinical Oncology’s (ASCO) 2010 Annual Meeting. That’s when we’ll learn about overall survival of patients, along with other important study details. So even though Delcath’s system met the primary endpoint, as they announced tonight, we don’t know exactly how long (or if) it increased overall survival among patients. The data looks good so far, but I prefer to stay wary and be ready for a surprise. Don’t get …

Continue Reading »

Delcath Surges on Phase III Clinical Data

Filed in GOld juniors, Gold Market, lead by on April 21, 2010 0 Comments

Delcath Systems (NASDAQ: DCTH ) surged 30% in after-hours trading Wednesday. The company announced positive clinical data for their proprietary liver cancer treatment system, The Delcath Percutaneous Hepatic Perfusion (PHP) device. The PHP system works by first isolating the patient’s liver from the rest of the circulatory system. This is accomplished using catheters and balloons, which are inserted via small incisions in the patient’s neck and legs. Highly-concentrated doses of chemotherapy drugs are then delivered directly to the diseased organ. After treatment, the blood is filtered and cleansed of potentially toxic drugs and returned to circulation. The system — which is unique as far as I know — allows doctors to target the liver with 10x higher doses of chemotherapy than are normally feasible. Since the drugs are targeted directly at the tumors, then filtered out of the bloodstream after treatment, DCTH thinks they can significantly increase dosage without increasing toxicity. It could prove to be an important life-extending development for patients who currently have few treatment options. The trial data announced this afternoon comes from Delcath’s phase III clinical trial, which enrolled patients who have melanoma that has spread to the liver. Patients who received treatment from the Delcath system had more than a 50% reduction in a primary study goal, “time to tumor reduction or death”. The results exceeded primary endpoint expectations and were statistically significant. In FDA-speak, that’s a good news for patients and investors. Here’s an excerpt from the company’s press release : Delcath Systems, Inc. (NASDAQ: DCTH), a development stage, oncology-focused, specialty pharmaceutical and medical device company, announced that its Phase III National Cancer Institute (NCI)-led multi-center clinical trial has successfully met the study’s primary endpoint of extended hepatic progression-free survival (hPFS) in patients with melanoma metastases to the liver based on an independently corroborated intent-to-treat analysis. Comparing treatment with the Delcath PHP System with melphalan to Best Alternative Care (BAC), based on independent core lab review of patient scans, the statistical analysis revealed that the PHP patients had a statistically significant longer median hPFS of 214 days compared to 70 days in the BAC arm. Reuters reports that the market for Delcath’s system to treat melanoma which has spread to the liver could be $745 million in the U.S. alone. Delcath is also proceeding with phase II clinical trials on primary liver cancers at the National Cancer Institute. The company’s current market cap was around $395m as of closing today (but it closed up 30% in after-hours trading). Full Trial Data To Be Announced June 5th While I’m bullish on Delcath (disclosure: I own the stock), it’s important to note that the full details of this trial won’t be available until June 5th, when the lead researcher presents at the American Society of Clinical Oncology’s (ASCO) 2010 Annual Meeting. That’s when we’ll learn about overall survival of patients, along with other important study details. So even though Delcath’s system met the primary endpoint, as they announced tonight, we don’t know exactly how long (or if) it increased overall survival among patients. The data looks good so far, but I prefer to stay wary and be ready for a surprise. Don’t get me wrong, the ASCO meeting is a great …

Continue Reading »

JUDGE DENIES Orly Taitz intervener motion to join health care lawsuit

Filed in Gold by on April 9, 2010 0 Comments

On April 6, 2010, Dr. Orly Taitz filed an intervener motion to petition the U.S. District Court, Northern District of Florida, to participate in the declaratory judgment action before that court by 13 state Attorneys General. Taitz made her motion as a Plaintiff of Right, or alternatively, with the Court’s permission. The thirteen plaintiffs are suing the Obama regime on the grounds that the Patient Protection and Affordable Care Act (the health care bill) violates the Constitution’s Commerce Clause at Article I, Section 8. However, on April 8, senior federal judge for the United States District Court for the Northern… Original Article: Forum: News/Activism

Continue Reading »

Mass Unemployment and the Current Economic Crisis

Filed in Bank Gold, economy, gld, Gold by on March 20, 2010 0 Comments

On March 17 Congress passed the “Hire Now Tax Cut” giving companies a break from paying Social Security taxes for the remainder of the year on any new workers hired who have been unemployed for at least 60 days. The legislation is a token response to the emerging consensus in both the mainstream and independent media that the economy’s unemployment problem is cumulative, structural and long term. But the prescription is entirely inadequate to the diagnosis. This should come as no surprise, as official sources have offered muddled and confusing accounts of the patient’s malaise. WRH permalink

Continue Reading »

TARP Repayments Push Geithner to Focus on Unemployment Credit

Filed in Gold Holdings, Gold Investing by on December 15, 2009 0 Comments

The U.S. banking industry moved outof intensive care when Citigroup Inc. and Wells Fargo & Co. saidyesterday they will repay their bailout funds. TreasurySecretary Timothy Geithner still can’t claim the patient ishealthy. The Treasury is in line TARP Repayments Push Geithner to Focus on Unemployment Credit

Continue Reading »

Church to celebrate feast of first modern medical doctor ever canonized

Filed in Gold by on November 15, 2009 0 Comments

CNA STAFF, Nov 15, 2009 / 04:45 am (CNA).- On November 16, the Church will celebrate the feast of St. Joseph Moscati, the first modern medical doctor to be canonized. Born on July 25, 1880 in Benevento, Italy, he lived out the Gospel through his position as a teacher and physician. There are a number of stories of Dr. Moscati paying close attention to the state of his patient's soul as well as the body, sometimes even bringing the patient back to the sacraments. The Catholic understanding of body and soul clearly informed his understanding of illness and medicine…. Original Article: Forum: News/Activism

Continue Reading »